MedTrace Logo

Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease

NCT00004293 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.

Conditions

  • Gaucher's Disease

Interventions

DRUG

glucocerebrosidase

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • John Barranger · University of Pittsburgh

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004293 on ClinicalTrials.gov